Literature DB >> 8817337

A model of mRNA splicing in adult lysosomal storage disease (glycogenosis type II).

N Raben1, R C Nichols, F Martiniuk, P H Plotz.   

Abstract

Glycogenosis type II is a recessively inherited disorder caused by mutations in the acid maltase (GAA) gene. Clinically, three different phenotypes are recognized: Infantile, juvenile and adult forms. A majority of compound heterozygous adult-onset patients carry a t-13g mutation in intron 1 associated with splicing out the first coding exon (exon 2). We have studied the mechanism of this mutation in a model system with wild-type and mutant minigenes expressed in a GAA deficient cell line. We have demonstrated that the mutation does not prevent normal splicing; low levels of correctly spliced mRNA are generated with the mutant construct. The data explain why the mutation is restricted to a milder, adult-onset phenotype. We also demonstrate that splicing out of exon 2 occurs with the wild-type construct, and thus represents alternative splicing which takes place in normal cells. Three splice variants (SV1, SV2 and SV3) are made with both the mutant and the wild-type constructs. Furthermore, as shown by RNAse protection assay, these mRNA variants are less abundant with the mutant construct. Thus, a major effect of the mutation appears to be a low splicing efficiency, since the total amount of all the transcripts generated from the mutant construct is reduced compared with the wild type. The removal of approximately 90% of the intron 1 (2.6 kb) sequence resulted in a dramatic increase in the levels of correctly spliced mRNA, indicating that the intron may contain a powerful transcriptional repressor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8817337     DOI: 10.1093/hmg/5.7.995

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  27 in total

1.  Splicing mutations in glycogen-storage disease type II: evaluation of the full spectrum of mutations and their relation to patients' phenotypes.

Authors:  Stefania Zampieri; Emanuele Buratti; Silvia Dominissini; Anna Lisa Montalvo; Maria Gabriela Pittis; Bruno Bembi; Andrea Dardis
Journal:  Eur J Hum Genet       Date:  2010-12-22       Impact factor: 4.246

2.  A mutation of COX6A1 causes a recessive axonal or mixed form of Charcot-Marie-Tooth disease.

Authors:  Gen Tamiya; Satoshi Makino; Makiko Hayashi; Akiko Abe; Chikahiko Numakura; Masao Ueki; Atsushi Tanaka; Chizuru Ito; Kiyotaka Toshimori; Nobuhiro Ogawa; Tomoya Terashima; Hiroshi Maegawa; Daijiro Yanagisawa; Ikuo Tooyama; Masayoshi Tada; Osamu Onodera; Kiyoshi Hayasaka
Journal:  Am J Hum Genet       Date:  2014-08-21       Impact factor: 11.025

3.  Seven cases of Pompe disease from Greece.

Authors:  M Kroos; P Manta; I Mavridou; F Muntoni; D Halley; R Van der Helm; D Zaifeiriou; A Van der Ploeg; A Reuser; H Michelakakis
Journal:  J Inherit Metab Dis       Date:  2006-08       Impact factor: 4.982

4.  Pompe disease in a Brazilian series: clinical and molecular analyses with identification of nine new mutations.

Authors:  Sueli M Oba-Shinjo; Roseli da Silva; Fernanda G Andrade; Rachel E Palmer; Robert J Pomponio; Kristina M Ciociola; Mary S Carvalho; Paulo S Gutierrez; Gilda Porta; Carlo D Marrone; Verônica Munoz; Anderson K Grzesiuk; Juan C Llerena; Célia R Berditchevsky; Claudia Sobreira; Dafne Horovitz; Thamine P Hatem; Elizabeth R C Frota; Rogerio Pecchini; João Aris Kouyoumdjian; Lineu Werneck; Veronica M Amado; José S Camelo; Robert J Mattaliano; Suely K N Marie
Journal:  J Neurol       Date:  2009-07-09       Impact factor: 4.849

Review 5.  Molecular genetics of Pompe disease: a comprehensive overview.

Authors:  Paolo Peruzzo; Eleonora Pavan; Andrea Dardis
Journal:  Ann Transl Med       Date:  2019-07

Review 6.  Diagnostic tools in late onset Pompe disease (LOPD).

Authors:  Olimpia Musumeci; Antonio Toscano
Journal:  Ann Transl Med       Date:  2019-07

Review 7.  Pompe Disease: From Basic Science to Therapy.

Authors:  Lara Kohler; Rosa Puertollano; Nina Raben
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

8.  A rare branch-point mutation is associated with missplicing of fibrillin-2 in a large family with congenital contractural arachnodactyly.

Authors:  C Maslen; D Babcock; M Raghunath; B Steinmann
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

Review 9.  The past and presence of gene targeting: from chemicals and DNA via proteins to RNA.

Authors:  T M Geel; M H J Ruiters; R H Cool; L Halby; D C Voshart; L Andrade Ruiz; K E Niezen-Koning; P B Arimondo; M G Rots
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-06-05       Impact factor: 6.237

10.  Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study.

Authors:  Claudio Semplicini; Pascaline Letard; Marie De Antonio; Nadjib Taouagh; Barbara Perniconi; Françoise Bouhour; Andoni Echaniz-Laguna; David Orlikowski; Sabrina Sacconi; Emmanuelle Salort-Campana; Guilhem Solé; Fabien Zagnoli; Dalil Hamroun; Roseline Froissart; Catherine Caillaud; Pascal Laforêt
Journal:  J Inherit Metab Dis       Date:  2018-08-28       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.